Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study. - Université de Lille Accéder directement au contenu
Article Dans Une Revue European Journal of Haematology Année : 2023

Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.

Nico Gagelmann
  • Fonction : Auteur
Dirk-Jan Eikema
  • Fonction : Auteur
Linda Koster
  • Fonction : Auteur
Tanja Netelenbos
  • Fonction : Auteur
Andrew Mcdonald
  • Fonction : Auteur
Roland Fenk
  • Fonction : Auteur
Achilles Anagnostopoulos
  • Fonction : Auteur
Gwendolyn van Gorkom
  • Fonction : Auteur
Michel Delforge
  • Fonction : Auteur
Donald Bunjes
  • Fonction : Auteur
William Arcese
  • Fonction : Auteur
Péter Reményi
  • Fonction : Auteur
Maija Itälä-Remes
  • Fonction : Auteur
Lorenz Thurner
  • Fonction : Auteur
Ali Zahit Bolaman
  • Fonction : Auteur
Yafour Nabil
  • Fonction : Auteur
Johan Lund
  • Fonction : Auteur
Patrick J. Hayden
  • Fonction : Auteur
Meral Beksac
  • Fonction : Auteur
Stefan Schönland
  • Fonction : Auteur

Résumé

Background No adequate data exist on the impact of multiple myeloma (MM) with extramedullary disease (EMD) after autograft and maintenance therapy. Methods We identified 808 patients with newly diagnosed MM who received first autograft, of whom 107 had EMD (83 paraskeletal and 24 organ involvement), and who had been reported to the EBMT registry December 2018. Distribution according to type of involvement was similar between the treatment groups (p = .69). For EMD, 46 (40%) received thalidomide, 59 (51%) lenalidomide, and 11 (10%) bortezomib. Results The median follow-up from maintenance start was 44 months. Three-year progression-free survival (PFS) was 52% (48%–57%) for no EMD, 56% (44%–69%) for paraskeletal involvement, and 45% (22%–68%) for organ involvement (p = .146). Early PFS (within first year) appeared to be significantly worse for organ involvement (hazard ratio, 3.40), while no significant influence was found after first year from maintenance start. Three-year overall survival (OS) was 81% (77%–84%), 88% (80%–96%), and 68% (47%–89%; p = .064), respectively. With thalidomide as reference, lenalidomide was significantly associated with better PFS and OS, whereas bortezomib appeared to improve outcome specifically in EMD. Conclusion Lenalidomide maintenance is standard of care for MM without EMD, whereas extramedullary organ involvement remains a significant risk factor for worse outcome, especially for early events after maintenance start.
Fichier principal
Vignette du fichier
European J of Haematology - 2023 - Gagelmann - Impact of newly diagnosed extramedullary myeloma on outcome after first.pdf (1.33 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY NC - Paternité - Pas d'utilisation commerciale

Dates et versions

hal-04427902 , version 1 (14-02-2024)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Nico Gagelmann, Dirk-Jan Eikema, Linda Koster, Tanja Netelenbos, Andrew Mcdonald, et al.. Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.. European Journal of Haematology, 2023, European Journal of Haematology, 111 (2), pp.181-190. ⟨10.1111/ejh.13981⟩. ⟨hal-04427902⟩
5 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More